P166 Experience with the use of yttrium-90 ibritumomab tiuxetan (Zevalin) in relapsed follicular lymphoma

✍ Scribed by J. Demeter; K. Balassa; M. D¨om¨ot¨or; M. Egyed; Z. Gasztonyi; H. Aryab; M. Gurzó; J. Iványi; Zs. Klucsik; L. Sréter; Zs. Nagy

• Book ID: 104323218
• Publisher: Elsevier Science
• Year: 2007
• Tongue: English
• Weight: 58 KB
• Volume: 21
• Category: Article
• ISSN: 0268-960X
• DOI: 10.1016/s0268-960x(07)70245-x

✦ Synopsis

cursor was set to the same position in each sample, where 5% of T/NK cells were Zap-70 negative. Zap-70 and CD38 labeling was determined on CD19+ cells. Results: With dichotomized evaluation of CD38 and Zap-70 expression 70% of the cases showed concordant results: 32% were Zap-70+/CD38+ and 38% were Zap-70 /CD38 . In 30% of the patients results were discordant. Parallel examinations of bone marrow (BM) and peripheral blood (PB) samples were compared in 18 patients. In all discordant cases (6 patients) Zap-70 values showed positivity in the BM specimens while the PB samples were negative. Longitudinal examinations were carried out 2 to 9 times few months apart in 24 patients (92 tests). Significant variability of the Zap-70 results was found in those cases where the test was repeated more than two times in contrast to CD38 expression which remained stable. The unstable Zap-70 results were not in connection with treatment protocol or CD38 bimodality. Conclusion: Expression of CD38 seems to be more stable over time than